tiprankstipranks
Trending News
More News >
Pharma Mar SA (PHMMF)
OTHER OTC:PHMMF

Pharma Mar SA (PHMMF) AI Stock Analysis

Compare
51 Followers

Top Page

Pharma Mar SA (PHMMF) vs. SPDR S&P 500 ETF (SPY)

Pharma Mar SA Business Overview & Revenue Model

Company DescriptionPharma Mar, S.A., a biopharmaceutical company, engages in the research, development, production, and commercialization of bio-active principles of marine origin for use in oncology in Spain, Italy, Germany, Ireland, rest of EU, the United States, and internationally. The company operates through three segments: Oncology, Diagnostics, and RNA interference. It develops and commercializes Yondelis for the treatment of soft tissue sarcomas and for ovarian cancer; Aplidin for treating multiple myeloma; and Zepzelca for treating patients with small cell lung cancer. The company also develops PM14 which is in phase II clinical trails for the treatment of solid tumors. In addition, it develops and markets diagnostics kits; and develops drugs with therapeutic activity based on reducing or silencing gene expression. The company was incorporated in 1986 and is based in Madrid, Spain.
How the Company Makes Money

Pharma Mar SA Financial Statement Overview

Summary
Pharma Mar SA is experiencing declining revenues and profitability, impacting its financial health. The balance sheet remains relatively strong with manageable leverage, but cash flow challenges pose a risk to financial stability. The company needs to focus on improving operational efficiency and cash flow generation to enhance its financial position.
Income Statement
62
Positive
Pharma Mar SA has shown a declining revenue trend over the past few years, with a notable decrease from 2020 to 2025. The TTM data shows a slight increase in total revenue compared to the previous year. The gross profit margin remains strong, indicating effective cost management, but the net profit margin has decreased significantly, reflecting reduced profitability. The EBIT and EBITDA margins have also declined, which indicates lower operational efficiency.
Balance Sheet
75
Positive
The company's balance sheet reflects a solid equity base with a strong equity ratio. The debt-to-equity ratio is manageable, signaling a balanced approach to leverage. However, the decrease in stockholders' equity over the years and fluctuations in total assets highlight potential concerns about asset management. The return on equity has decreased over time, reflecting challenges in generating returns for shareholders.
Cash Flow
55
Neutral
The cash flow statement shows significant variability, with negative free cash flow in the TTM period, indicating cash flow challenges. The operating cash flow to net income ratio is concerning, as it reflects difficulties in converting accounting profits into cash. However, the company has managed to maintain a positive operating cash flow in prior years, which suggests some potential for cash flow recovery.
Breakdown
TTMDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income StatementTotal Revenue
175.75M174.85M158.15M196.34M229.83M269.96M
Gross Profit
165.93M166.67M148.54M182.70M213.39M256.24M
EBIT
6.56M6.47M-3.83M44.07M92.45M155.94M
EBITDA
21.93M21.23M4.55M52.07M104.08M155.94M
Net Income Common Stockholders
19.88M26.13M1.14M49.36M92.86M137.26M
Balance SheetCash, Cash Equivalents and Short-Term Investments
140.85M154.53M162.56M182.42M201.88M195.52M
Total Assets
333.50M349.64M340.52M393.26M368.39M330.26M
Total Debt
51.94M51.08M43.67M42.63M49.33M56.66M
Net Debt
-8.35M-12.16M-16.36M-107.18M-64.02M-39.55M
Total Liabilities
136.02M141.28M147.08M170.30M190.47M227.54M
Stockholders Equity
197.47M208.36M193.44M222.96M177.92M102.72M
Cash FlowFree Cash Flow
-18.29M-9.48M-29.40M29.47M17.87M275.94M
Operating Cash Flow
-9.56M6.03M-13.45M38.32M25.68M278.94M
Investing Cash Flow
39.33M1.03M-43.05M10.88M18.47M-119.01M
Financing Cash Flow
-5.43M-5.35M-32.14M-13.37M-27.41M-73.82M

Pharma Mar SA Peers Comparison

Overall Rating
UnderperformOutperform
Sector (54)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
$1.72B78.7510.15%0.73%
54
Neutral
$5.31B3.28-45.10%2.80%16.76%0.02%
€2.37B232.500.69%1.33%
€1.34B11.9816.04%2.97%
€6.32B26.773.37%
€263.54M23.595.11%1.24%
€2.80B20.2525.24%1.62%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
PHMMF
Pharma Mar SA
95.77
55.22
136.18%
GB:0O9B
Almirall
11.16
1.70
17.97%
GB:0K9H
Faes Farma
4.28
0.62
16.94%
GB:0RDV
Grifols
7.68
1.12
17.07%
GB:0RB1
LABORATORIO REIG JOFRE
3.19
0.13
4.25%
GB:0ILL
Laboratorios Farmaceuticos Rovi
55.20
-32.91
-37.35%
Glossary
OutperformA stock rated as "Outperform" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock is likely to deliver higher returns compared to the average returns of other stocks in the same sector or market index. Investors might consider this stock a good buying opportunity.
NeutralA stock rated as "Neutral" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly attractive nor unattractive for investment. Investors may consider holding onto the stock, as it is not expected to either significantly outperform or underperform the market.
UnderperformA stock rated as "Underperform" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock may deliver lower returns compared to the average returns of other stocks in the same sector or market index. Investors might consider selling the stock or avoiding it as an investment.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.